Principal Investigator | Organization | Project Title | Data Availability | Analyte | Matrix | Included Enrollment Cohorts | Subcategories included | Visit(s) | Project ID | Notes | ||||
Collaboration powered by Smartsheet | Report Abuse | ||||||||||||||
1 | Peggy Taylor, PhD | BioLegend | aSyn Measurements in Longitudinal CSF Samples From De Novo, PD, CT, SWEDD, Prodromal, & Genetic Cohorts | Currently available |
| CSF | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline, 6, 12, 24, 36 months | 102, 103, 111, 124 | PD, HC, SWEDD through yr 3, prodromal & genetic through yr 1 | |||
2 | Jessie Ni, PhD | BioLegend | Pilot and Large-Scale Study for ASYN in PPMI CSF | Bridging study available |
| CSF | Healthy Control Parkinson Disease | Bridging Study in 100 previously evaluated samples | 201 | |||||
3 | Les Shaw, PhD | UPenn | A-beta 1-42, t-tau and p-tau 181 Measurements in PPMI CSF Samples using xMAP/Luminex Multiplex Immunoassay & Roche Elecsys | Currently available |
| CSF | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline, 6, 12, 24, 36 months | 110, 125 | Innogentics: PD, HC, & SWEDD through yr 1; Elecsys: PD, HC, & SWEDD through yr 3, prodromal & genetic through yr 1 | |||
4 | Les Shaw, PhD | UPenn | PPMI CSF A-beta42, t-tau, and p-tau 181 Analysis 2019 | Currently available |
| CSF | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 months | 159 | 75 Bridging study & 2,000+ remaining PPMI samples not yet analyzed from previous efforts | |||
5 | Clemens Scherzer, MD | Harvard | Evaluation of PD-linked Transcripts in PPMI | Currently available |
| RNA from whole blood | Healthy Control Parkinson Disease | Baseline | 105 | |||||
6 | Judith Potashkin, PhD | Rosalind & Franklin University | Whole Blood RNA Biomarkers of PD | Currently available |
| RNA from whole blood | Healthy Control Parkinson Disease | Baseline | 114 | |||||
7 | Martin Rabey, MD | BioShai Ltd. | Validation of a Blood-based Gene Expression Assay for Early Diagnosis & Monitoring Disease | Currently available |
| RNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline, 12, 24, 36 months | 119 | |||||
8 | Kendall Van Keuren-Jensen, PhD | TGen Foundation | RNAseq in PPMI | Currently available (summary files, raw data for cloud transfer, & data explorer) |
| RNA from whole blood | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baselilne, 6, 12, 24, 36 months | 131, 133 | Data available as summary files, raw data for cloud transfer, & data explorer | |||
9 | Matthew Farrer, PhD | University of BC | Clinical, Imaging, & Plasma & CSF Correlates of aSyn Genomic Variability | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease | Baseline | 115 | |||||
10 | Travis Dunckley, PhD; Paula Desplats, PhD | Arizona State University; UCSD | Comprehensive Methylation Profiling of the PPMI Cohort | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease Prodromal | LRRK2 subjects | Baseline, 12, 24, 36 months | 140 | ||||
11 | Sulev Koks, MD, PhD | Murdoch University | Association of Repetitive Elements with Parkinson's Disease Risk and Progression in the PPMI Cohort | Currently available |
| DNA | Healthy Control Parkinson Disease | Baseline | 160 | |||||
12 | Kimberly Billingsley, PhD | NIH | Identifying the Role of Structural Variants in PD | Expected Q2 2023 |
| DNA | Healthy Control Parkinson Disease | Various | 179 | |||||
13 | Christos Proukakis, MD, PhD | University College London | Detection of GBA Mutations by Combination of Illumina & Nanopore Sequencing | Currently available |
| DNA | Parkinson Disease Prodromal | GBA subjects | Various | 195 | ||||
14 | Dwight German, PhD | UT Southwestern | Blood biomarker for PD | Currently available |
| Serum | Healthy Control Parkinson Disease | Baseline | 123 | |||||
15 | Maria Teresa Pellecchia, PhD | University of Salerno | Insulin-like Growth Factor-1 as a Biomarker of Early Cognitive Impairment in PD | Currently available |
| Serum | Healthy Control Parkinson Disease | Baseline | 113 | |||||
16 | Danielle Graham, PhD; Brit Mollenhauer, MD | Biogen; Paracelsus Elena Klinik | Investigation of Neurofilament Light Chain in Serum from the PPMI Cohorts as Progression Marker for PD | Currently available |
| Serum | Healthy Control Parkinson Disease Prodromal | Genetic subjects | PD & HC: Baseline, 6, 12, 24, 36, 60 months; Prodromal & genetic cohorts: Baseline, 6, 12, 24, 36 months | 144 | ||||
17 | George Tofaris, MD, PhD | University of Oxford | Serum Neuronal Exosomes as Predictive or Dynamic Biomarkers in PD | Expected Q2 2023 |
| Serum | Parkinson Disease Prodromal | GBA & LRRK2 subjects | Baseline | 204 | ||||
18 | Peter Lewitt, MD | Henry Ford Health System | Polyamine Biomarkers of Parkinson Disease Progression |
| CSF Serum | Healthy Control Parkinson Disease | Baseline, 24 months | 189 | ||||||
19 | Alice Chen-Plotkin, MD, MSc | UPenn | Plasma Apolipoprotein A1 Level as a Biomarker in Parkinson’s Disease | Currently available |
| Plasma | Healthy Control Parkinson Disease | Baseline, 6, 12 months | 112 | |||||
20 | Shawn Ritchie, PhD | Med-Life Discoveries | Validation of Plasmalogen Augmentation as a Viable Drug Target in PD | Currently available |
| Plasma | Healthy Control Parkinson Disease SWEDD (legacy) | Genetic subjects | Baseline | 182 | ||||
21 | Pablo Sardi, PhD | Sanofi | GBA-Related Biomarkers in Parkinson's Disease | Currently available |
| CSF Plasma Whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline, 12, 24, 36 months | 132, 135 | |||||
22 | Jennifer Van Eyk, PhD | Cedars-Sinai | Post-Translational Modification & Protein Quantification of Plasma & CSF |
| CSF Plasma | Healthy Control Parkinson Disease | Baseline & 3 longitudinal timepoints | 177 | ||||||
23 | Eline Appelmans, PhD | FNIH | Targeted Proteomics in AMP PD | Currently available |
| CSF Plasma | Healthy Control Parkinson Disease | Baseline & 3 longitudinal timepoints | 196 | |||||
24 | Marion Buckwalter, PhD | Stanford | Adaptive Immune Markers for Predicting Cognitive Decline in PD | Currently available |
| CSF Plasma | Healthy Control Parkinson Disease | Baseline, 48 months | 181 | |||||
25 | Michael Schwarzschild, PhD | MGH & Denali | Metabolomic Analysis of Penetrance, Prognosis, & Tracking Biomarkers of LRRK2 PD | Plasma available; CSF Expected Q3 2023 |
| CSF Plasma | Healthy Control Parkinson Disease Prodromal | GBA & LRRK2 subjects | Plasma: Baseline,12, 24 months; CSF: Baseline only | 180 | ||||
26 | Gavin Hudson, PhD | Newcastle University | The Role of Cell-Free Mitochondrial DNA in Neurodegenerative Disease | Currently available |
| CSF | Healthy Control Parkinson Disease | Baseline, 36 months | 130 | |||||
27 | Thomas Kremer, PhD; Kristen Taylor, PhD | Roche | CSF Neurotransmitter Metabolites as Promising Diagnostic & Disease Severity Biomarkers in Early-Stage PD Patients | Currently available |
| CSF | Healthy Control Parkinson Disease | Baseline, 12, 24 months | 122 | |||||
28 | Richard Batrla-Utermann, PhD | Roche | Roche NeuroTool Kit | Currently available |
| CSF | Healthy Control Parkinson Disease | Baseline, 6, 12, 24, 36, 48 months | 152 | |||||
29 | Fiona Elwood, PhD | Novartis | Identification of Proteins & Protein Networks in Human CSF That Differentiate Within PD Patients | Currently available |
| CSF | Healthy Control Parkinson Disease Prodromal | Genetic subjects | Baseline | 151 | ||||
30 | Liana Rosenthal, MD | John Hopkins | Is Poly ADP-ribose in the CSF a Biomarker for PD Diagnosis or Progression? | Expected Q2 2023 |
| CSF | Healthy Control Parkinson Disease | Baseline, 6, 12, 18, 24, 36,48, 60 months | 165 | |||||
31 | Claudio Soto, PhD | Amprion | Monitoring the Progression & Pre-clinical Diagnosis of PD by Detection of aSyn Oligomers in CSF Using the PMCA Assay | Phase 1 Currently available; Phase 2 expected Q4 |
| CSF | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Phase 1: BL, 36, mo; Phase 2: PD, HC, SWEDD at BL, prodromals at all visits, SNCA at all visits, LRRK2/GBA PD at BL and NMC at BL & all visits for phenoconverted | 155 | Phase 1 (Baseline & 36 months) PD, CT, SWEDD currently available; remaining data expected EOY | |||
32 | Roland Heym, PhD | Abbvie | Evaluation of Seeding-competent aSyn in the CSF as a Biomarker for Parkinson’s Disease | Currently available |
| CSF | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline, 36 months | 173 | |||||
33 | Byron Caughey, PhD | NIH | aSyn Seeding Assay Round Robin- NIH | Currently available |
| CSF | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline, 36 months | 172 | |||||
34 | Kirsten Taylor, PhD | Roche | aSyn PMCA Assay at Amprion | Currently available |
| CSF | Healthy Control Parkinson Disease | Baseline, 12, 24 months | 176 | |||||
35 | Kalpana Merchant, PhD | TransThera | Do Urinary BMP Levels Change with Disease Progression in Idiopathic & Genetic PD? | Currently available |
| Urine | Healthy Control Parkinson Disease Prodromal | GBA & LRRK2 subjects | PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months | 145 | ||||
36 | Sebastian Virreira Winter, PhD | OmicEra | Targeted & Untargeted MS Based Proteomics of Urine in PD | Currently available |
| Urine | Healthy Control Parkinson Disease Prodromal | GBA & LRRK2 subjects | PD, HC, & GBA: Baseline only; LRRK2: Baseline, 12, 24 months | 190 | ||||
37 | Eleanor Coffey, PhD | Turku Centre for Biotechnology | PD Signature Validation Project Related to "Improving Patient Diagnosis, Stratification & Disease Monitoring in PD" |
| PBMCs | Healthy Control Parkinson Disease Prodromal | Genetic subjects | 3 longitudinal timepoints | 170 | |||||
38 | Diana Matheoud, PhD | Université de Montréal | Mitochondria Autoreactivity in PD Patients as a New Biomarker for the Disease | Sample shipment pending |
| PBMCs | Healthy Control Parkinson Disease | 54, 96 months | 178 | |||||
39 | Satpal Virdee, PhD, | University of Dundee | Profiling PINK1-Parkin Functionality in Patient Fibroblasts Using Chemical Probes | Currently available |
| Fibroblasts | Healthy Control Parkinson Disease | n/a | 127 | |||||
40 | Marlene Jacobson, PhD | University of Dundee | Investigating the Effect of Small Molecules to Rescue Lysosomal & GBA-1 Deficiencies in GBA-PD | Currently available |
| Fibroblasts | Healthy Control Parkinson Disease | n/a | 158 | |||||
41 | Alejandro Pezzulo, MD | University of Iowa | Multidisciplinary Analysis of Metabolic Dysregulation in Parkinson's Disease | Expected Q1 2023 |
| Fibroblasts | Healthy Control Parkinson Disease | n/a | 194 | |||||
42 | Xinnan Wang, PhD | Stanford University | Miro, a Biomarker for Parkinson’s Disease | Currently available |
| Fibroblasts iPSCs | Healthy Control Parkinson Disease Prodromal | Genetic subjects | n/a | 129 | ||||
43 | Lalitha Madhavan, PhD | University of Arizona | Development of a Biomarker Platform for Parkinson’s disease Using Patient-derived Cells |
| Fibroblasts iPSCs | Healthy Control Parkinson Disease | n/a | 175 | ||||||
44 | Nilima Prakash, PhD | Hamm-Lippstadt University of Applied Sciences | Altered Calcium Activity Patterns in Developing Dopaminergic Neurons from PD Patients as an Early Indicator of Disease Predisposition or Progression | Expected Q2 2023 |
| Fibroblasts iPSCs | Healthy Control Parkinson Disease | n/a | 136 | |||||
45 | Rachit Bakshi, PhD | MGH/MIND | Urate & Nrf2 Pathway Effects on Mutant LRRK2 Toxicity in iPSC-Derived DA Neurons | Currently available |
| iPSCs | Healthy Control Parkinson Disease Prodromal | LRRK2 subjects | n/a | 137 | ||||
46 | Andy Singleton, PhD | NIA | The Foundational Data Initiative | Currently available; interactive portal currently under development, expected Q3 2021 |
| iPSCs | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | n/a | 150 | Data portal under development | |||
47 | Mark Cookson, PhD | NIA | LRRK2 Genetic Risk Variants in PD | Expected Q3 2023 |
| iPSCs | Healthy Control Parkinson Disease Prodromal | Genetic subjects | n/a | 139 | ||||
48 | Nic Dzamko, PhD | University of Sydney | Inflammatory phenotypes in differentiated human LRRK2 & GBA mutation IPS cell lines | Currently available |
| iPSCs | Healthy Control Parkinson Disease Prodromal | GBA & LRRK2 subjects | n/a | 141 | ||||
49 | Aaron Day Williams | Flagship 60 | Investigation of Phenotypic Differences Between Familial PD, Idiopathic PD and Controls in Patient-derived iPSCs | Currently available |
| iPSCs | Healthy Control Parkinson Disease Prodromal | LRRK2 subjects | n/a | 156 | ||||
50 | Matt LaVoie, PhD | Brigham & Women’s, Harvard | Role of LRRK2 in Gcase-mediated Alterations in Lysosome Functions & aSyn Metabolism | Expected Q2 2023 |
| iPSCs | Parkinson Disease | GBA subjects | n/a | 149 | ||||
51 | Dimitri Krainc, MD | Northwestern University | Convergence of LRRK2 & GBA1 in the Pathogenesis of Parkinson’s Disease | Expected Q1 2023 |
| iPSCs | Healthy Control Parkinson Disease | LRRK2 subjects | n/a | 148 | ||||
52 | Dong-Gyu Jo, PhD | Sungkyunkwan University | Study for the Propagation of aSyn (Screening the Propagation Relative Genes) | Expected Q1 2023 |
| iPSCs | Healthy Control Parkinson Disease | GBA & LRRK2 subjects | n/a | 174 | ||||
53 | Ellen Sidransky, MD | NIH | Development of Novel TRPML1 Activator for Treatment of PD |
| iPSCs | Healthy Control Parkinson Disease | n/a | 154 | ||||||
54 | Magdalene Moran, PhD | Caraway Therapeutics | Developing TMEM175 Activators as Therapeutics for PD | Expected Q2 2023 |
| iPSCs | Parkinson Disease | GBA subjects | n/a | 199 | ||||
55 | Maximiliano Gutierrez, PhD | Francis Crick Institute | The Role of LRRK2 Kinase Activity in Human Macrophage Function | Expected Q1 2023 |
| iPSCs | Parkinson Disease | LRRK2 subjects | n/a | 161 | ||||
56 | Antony Cooper, PhD | Garvan Institute | Phenotypic Confirmation of a Potential New Genetic Subtype of Parkinson’s Disease | Expected Q1 2023 |
| iPSCs | Healthy Control Parkinson Disease | n/a | 188 | |||||
57 | Robert Krencik, PhD | Houston Methodist Research Institute | Midbrain Asteroids to Interrogate Human Astrocyte Function within Neural Networks |
| iPSCs | Healthy Control Parkinson Disease | GBA subjects | n/a | 168 | |||||
58 | Claudio Soto, PhD | University of Texas | A Novel Model of Parkinson’s Disease in Lab-generated Mini-brains | Expected Q1 2023 |
| iPSCs | Healthy Control Parkinson Disease | LRRK2 & SNCA subjects | n/a | 166 | ||||
59 | Erika Holzbaur, PhD | UPenn | Investigating Mitochondrial Trafficking Deficits Across PD Models | Expected Q2 2023 |
| iPSCs | Healthy Control | Genetic subjects | n/a | 198 | ||||
60 | Thomas Schwarz, PhD | Boston Children’s Hospital | Mitochondrial Transport Defects as a Potential Biomarker in Patient-derived Cells | 10HC, 3 SNCA, 1 LRRK2, 2 PD lines available; Remaining expected Q1 2023 |
| iPSCs | Healthy Control Parkinson Disease | Genetic subjects | n/a | 153 | ||||
61 | Emmanouil Metzakopian, PhD | University of Cambridge | High-throughput Single Cell Unbiased Lipidomics Assay in Human iPSC-derived | Expected Q3 2023 |
| iPSCs | Healthy Control Parkinson Disease Prodromal | Genetic subjects | n/a | 183 | ||||
62 | Deniz Kirik, MD, PhD | University of Sydney | Circuitry and Brain-body Interactions | Expected Q1 2024 |
| iPSCs | Parkinson Disease Prodromal | LRRK2 & SNCA subjects | n/a | 193 | ||||
63 | Xiqun Chen, MD, PhD | Mass General Hospital | From Cancer Associations to Altered Immunity in the Pathogenesis of Parkinson’s Disease | Expected Q2 2024 |
| iPSCs | Healthy Control Parkinson Disease | LRRK2 subjects | n/a | 197 | ||||
64 | Daphne Koller, PhD | Insitro | Insitro PPMI Cell Line Application | Expected Q2 2023 |
| iPSCs | Healthy Control Parkinson Disease | GBA & LRRK2 subjects | n/a | 187 | ||||
65 | Manoj Pandey, PhD | Cincinnati Children’s Hospital | Setting up the Translational Value of Complement 5a Induction of Brain Inflammation & Neuronal Loss in Human Patients w/ Parkinson’s Disease | Expected Q2 2023 |
| iPSCs | Healthy Control Parkinson Disease | GBA subjects | n/a | 167 | ||||
66 | Kiroaki Kaku, PhD | Western Michigan University | The Role of FAIM in Parkinson’s Disease | Expected Q3 2023 |
| iPSCs | Parkinson Disease | GBA & SNCA subjects | n/a | 206 | ||||
67 | Adam Mamais, PhD | University of Florida | Converging Pathways of LRRK2 & PINK1 Biology Impacting Iron Homeostasis & Mitochondrial Function | Expected Q2 2023 |
| iPSCs | Healthy Control Parkinson Disease | LRRK2 subjects | n/a | 202 | ||||
68 | Andrew Singleton, PhD | NIA | Selected Genetic Variants Genotyped Using NeuroX Array | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline | 106/107 | ||||
69 | Andrew Singleton, PhD | NIA | GBA Sequencing | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline | 126 | |||||
70 | Andrew Singleton, PhD | NIA | Immunochip Genotyping on DNA Samples from PPMI | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline | 108 | |||||
71 | Andrew Singleton, PhD | NIA | Exome Sequencing of PPMI samples | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline | 116 | |||||
72 | Andrew Singleton, PhD | NIA | Whole Genome Sequencing & Analysis of PPMI Prodromal & Genetic Cohorts & Genetic Registry | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline | 118 | ||||
73 | Andrew Singleton, PhD | NIA | APOE4 Genotyping | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline | 104 | |||||
74 | Dena Hernandez, PhD | NIA | DNA Methylation in PPMI | Currently available |
| DNA from whole blood | Healthy Control Parkinson Disease SWEDD (legacy) | Baseline | 120 | |||||
75 | Cornelis Blauwendraat, PhD | NIA | Long read DNA sequencing of the PPMI cohort | Expected Q3 2023 |
| DNA from whole blood | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | Baseline | 171 | ||||
76 | Rebecca Selzer, PhD | FUJIFILM Cellular Dynamics, Inc. | Production and Commercialization of Differentiated Cell Types | Expected Q3 2023 |
| iPSCs | Healthy Control Parkinson Disease Prodromal SWEDD (legacy) | Genetic subjects | n/a | 218 | Differentiation into commercially available dopaminergic neurons | |||
77 | Anumantha Kanthasamy, PhD | Iowa State University | PPMI a-Syn Skin Seeding Assay | Expected Q3 2023 |
| Skin | Healthy Control Parkinson Disease | Baseline | 211 | |||||
78 | Karen MacLeod, Claudio Soto, PhD | Amprion | Development and Optimization of Semi-Quantitate PMCA for Analysis of Soluble ASYN Aggregates in CSF in Amprion's Clinical Laboratory | Currently available |
| CSF | Healthy Control Parkinson Disease | Various | 207 | Used warmed CSF from various visits | ||||
79 | Khalil Ramadi | New York University | Neural Chemical Delivery System for Treatment of Parkinson's Disease | Expected Q3 2024 | Fibroblasts iPSCs | Healthy Control Parkinson Disease | n/a | 216 | ||||||
80 | Deniz Kirik | University of Sydney | An in vivo approach to elucidate the pathobiology of PD-associated genes using human diseased neurons | Expected Q4 2023 | Fibroblasts iPSCs | Healthy Control Parkinson Disease | n/a | 193 | ||||||
81 | Anthony Schapira | UCL Medical School | The genome-microbiome axis in the cause of Parkinson disease: Mechanistic insights and therapeutic implications from experimental models and a genetically stratified patient population. | Expected Q1 2024 | iPSCs | Healthy Control Parkinson Disease | n/a | 223 | ||||||
82 | Bahareh Ajami, Dario Alessi | Oregon Health & Science University, University of Dundee | Investigating the influence of genetic risk factors of PD on peripheral immune cells to identify potential biomarkers for prediction of conversion of non-manifesting to manifesting carriers. | Expected Q3 2023 | PBMCs Plasma | Parkinson Disease | n/a | 213, 213 | ||||||
83 | Céline Galvagnion | University of Copenhagen | Understanding selective neuronal vulnerability in the context of Parkinson's Disease | Expected Q1 2024 | iPSCs | 224 | ||||||||
84 | Julian Peter Sefrin | Abbvie | Evaluation of TMPRSS5 (Spinesin) in the CSF as a potential biomarker for early Parkinson’s disease diagnosis and progression | Currently available | CSF | 219 | ||||||||
85 | Massimiliano Bianchi | Ulysses Neuroscience Ltd | Validation of microtubule dynamics as a novel target in Parkinson’s disease | Expected Q2 2023 | iPSCs | n/a | 203 | |||||||
86 | Omar Mabrouk | Biogen | CSF total LRRK2 measurements as a Biomarker in genetic PD | Expected Q1 2023 | CSF | 221 | ||||||||
87 | Zinnhardt | Roche | Identification of NLRP3 Inflammasome-related biomarkers in PPMI CSF Samples | Currently available | CSF | 209 | ||||||||
88 | Susanna Narkilahti | University of Tampere | Electrophysiological Phenotype Characterization of iPSC-derived Neuronal Cells with PD-linked LRRK2 Mutations during Network Formation and Alpha-Synuclein Seeded Aggregation | Expected Q2 2024 | iPSCs | n/a | 227 | |||||||
89 | Sonia Gandhi | University College London | Defining mechanisms in neurons and oligodendrocytes that drive progression in Parkinson’s | Expected Q4 2024 | iPSCs | n/a | 229 | |||||||
90 | Rhalena Thomas | McGill University | A pipeline for massive multiplexing of iPSC-derived dopaminergic neurons and microglia for cohort-scale transcriptomics in PD | Expected Q4 2024 | iPSCs | n/a | 230 | |||||||
91 | Lezanne Ooi | University of Wollongong | Metabolic phenotyping in PD dopaminergic neurons and neuronal-glial co-cultures using high-throughput single-cell metabolomics and lipidomics | Expected Q2 2024 | iPSCs | n/a | 231 | |||||||
92 | Gist Croft | The New York Stem Cell Foundation | A cohort-wide resource of transcriptomic and morphological phenotypes in defined neural cell types | Expected Q2 2024 | iPSCs | n/a | 232 | |||||||
93 | Laurent Roybon | Lund University | Uncovering proteomic alterations in Parkinson’s disease using patient-specific iPSC-derived brain cells | Expected Q2 2024 | iPSCs | n/a | 233 | |||||||
94 | Laurent Roybon | VARI | Omic-based analyses of PD iPSC-derived brain cells | Expected Q3 2024 | iPSCs | n/a | 234 | |||||||
95 | Lalitha Madhavan | University of Arizona | Deep phenotyping of PD relevant mitochondrial and autophagic mechanisms in human iPSC-derived neural cells | Expected Q4 2024 | iPSCs | n/a | 235 | |||||||
96 | Souvik Modi | ESYA Labs | ESYA PD360: A multi-parametric platform for establishing a novel lysosome-based biomarker and identifying therapeutic interventions for Parkinson’s Disease | Expected Q1 2024 | Fibroblasts | n/a | 236 | |||||||
97 | Daniel Ysselstein | Vanqua Bio | Glucocerebrosidase Activation as a Therapeutic Strategy for Parkinson’s Disease | Expected Q1 2024 | iPSCs | n/a | 239 | |||||||
98 | Hilde Nilsen | Oslo University Hospital | Mitochondrial Transcription regulation via Base Excision Repair | Expected Q1 2024 | iPSCs | n/a | 241 | |||||||
99 | Luis Concha | Amprion | Evaluation of αSyn seed levels in prodromal cases by means of a semi-quantitative seed amplification assay & Validation of Clinical Accuracy of the Rapid Qualitative αSynuclein Seed Amplification Assay in the Amprion Clinical Laboratory | Expected Q1 2024 | CSF | 242 |